Mercer Global Advisors
LBRX

Mercer Global Advisors’s LB Pharmaceuticals LBRX Stock Holding History

Mercer Global Advisors’s Portfolio LBRX Stock Details LBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.93K Buy
+152
New +$4.46K ﹤0.01% 5357

Other funds holding LBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mercer Global Advisors's LBRX Position: Q2 2026 in Review

Mercer Global Advisors opened a new position in LB Pharmaceuticals (LBRX) in Q2 2026: 152 shares worth $4.93K. The stake represents ﹤0.01% of the portfolio and ranks #5357 among its holdings.

63 funds tracked by Wall St. Rank hold LBRX as of Q2 2026.

  • Mercer Global Advisors held 152 shares of LB Pharmaceuticals worth $4.93K as of Q2 2026.
  • LB Pharmaceuticals was a new Mercer Global Advisors position in Q2 2026.
  • LB Pharmaceuticals made up ﹤0.01% of Mercer Global Advisors's portfolio in Q2 2026, its #5357 holding.
  • 63 funds tracked by Wall St. Rank held LB Pharmaceuticals as of Q2 2026.

Based on Mercer Global Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.